Plinabulin

DRUG9 trials

Sponsors

University of Washington, BeyondSpring Pharmaceuticals Inc., Salma Sabbour, M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center

Conditions

ALK Gene TranslocationAdvanced Bladder CarcinomaAdvanced Lung Non-Small Cell CarcinomaAdvanced Malignant Solid NeoplasmAdvanced MelanomaAdvanced Merkel Cell CarcinomaAdvanced Renal Cell CarcinomaChemotherapy-induced Neutropenia

Phase 1

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

TerminatedNCT02846792

University of WashingtonALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma +3

Start: 2017-06-14End: 2018-08-16Updated: 2019-03-04

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

CompletedNCT03575793

Salma SabbourLung Cancer, SCLC

Start: 2018-09-06End: 2024-07-01Updated: 2026-01-20

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

TerminatedNCT04902040

M.D. Anderson Cancer CenterAdvanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm +32

Start: 2021-04-14End: 2025-02-27Updated: 2026-04-30

Phase 2

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

CompletedNCT04227990

BeyondSpring Pharmaceuticals Inc.Chemotherapy-induced Neutropenia

Start: 2017-11-27End: 2019-01-03Updated: 2020-01-18

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

CompletedNCT04345900

BeyondSpring Pharmaceuticals Inc.Chemotherapy-induced Neutropenia

Start: 2017-04-05End: 2018-04-20Updated: 2024-05-16

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Active, not recruitingNCT05130827

Memorial Sloan Kettering Cancer CenterMultiple Myeloma

Start: 2021-12-21End: 2026-11-30Updated: 2025-12-24

Phase 3

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

CompletedNCT03102606

BeyondSpring Pharmaceuticals Inc.Chemotherapy-induced Neutropenia

Start: 2018-05-29End: 2021-02-08Updated: 2024-08-29

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.Chemotherapy-induced Neutropenia

Start: 2019-10-23End: 2025-09-25Updated: 2021-01-15

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

Not yet recruitingNCT07361484

BeyondSpring Pharmaceuticals Inc.Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance

Start: 2026-06-01End: 2029-12-01Target: 442Updated: 2026-01-23

Related Papers

Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers.

2025-06-27

Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.

2024-08-213 citations

732 Immune activation with plinabulin enhances anti-tumor response combining radiation with immune checkpoint blockade

Regular and Young Investigator Award Abstracts2023-10-312 citations

603 Phase II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): big ten cancer research consortium (BTCRC-LUN17–127) study

Regular and Young Investigator Award Abstracts2023-10-31

Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.

Journal of Clinical Oncology2023-06-01

Prevention of chemotherapy-induced neutropenia (CIN) with plinabulin (Plin) vs placebo (Plac) in patients (pts) with non-small cell lung cancer (NSCLC) treated with docetaxel (Doc): A pooled analysis from 3 randomized trials.

Journal of Clinical Oncology2023-06-01

Abstract P1-12-10: Superior Effectiveness of Plinabulin (Plin) versus No-Treatment for Docetaxel (Doc)-Induced Neutropenia (N) and other Hematologic Complication in Breast Cancer (BC) Patients

Cancer Research2023-03-01

A Bioinformatic Approach to the Clinical Evaluation of Linear Commitment Versus Cloud (Continuum of Low Primed UnDifferentiated) Models for Hematopoiesis Using Plinabulin Clinical Trial Data

Blood2022-11-15

Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo).

Journal of Clinical Oncology2022-06-011 citations

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors

JAMA Network Open2022-01-2724 citations

Plinabulin Rapidly (within 24 Hours) Reverses Myelosuppression Induced By Chemotherapy

Blood2021-11-051 citations

A phase I trial of plinabulin in combination with nivolumab and ipilimumab in patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study.

Journal of Clinical Oncology2021-05-204 citations

Head-to-head comparison of single agent (SA) plinabulin (Plin) versus pegfilgrastim (Peg) for the prevention of chemotherapy-induced neutropenia (CIN) in the phase 3 trial PROTECTIVE-1.

Journal of Clinical Oncology2021-05-202 citations

Abstract PS13-34: Differential efficacy of pegfilgrastim (Peg) in patients (pts) with breast cancer (BC) versus other cancer types for the prevention of docetaxel (Doc) chemotherapy-induced neutropenia (CIN)

Cancer Research2021-02-15

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non–Small Cell Lung Cancer

JAMA Oncology2020-09-2431 citations

Head-to-head comparison of the non-G-CSF small molecule single agent (SA) plinabulin with SA pegfilgrastim for the prevention of docetaxel chemotherapy (chemo)-induced neutropenia (CIN) in the protective-1 trial.

Journal of Clinical Oncology2020-05-20

Effect of plinabulin, a novel late-clinical stage immunotherapeutic agent on the adaptive and innate immune system.

Journal of Clinical Oncology2020-02-041 citations

A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin)

Blood2019-11-131 citations

Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)

Blood2019-11-131 citations

Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis

Blood2019-11-13

6 more papers not shown